ADMA
BEARISH
$15.15
Live
ADMA Biologics, Inc. · NASDAQ
Target $25.67
(+69.4%)
$13.76
52W Range
$25.67
At a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Confidence
85%
ADMA's Piotroski F-Score of 3/9 indicates weak financial health, signaling distress risk despite strong profitability metrics. The company trades at a high P/E of 25.25 and Price/Sales of 7.07, significantly above sector averages, suggesting overvaluation. While gross and operating margins are impressive (57.38% and 45.09%), earnings have collapsed YoY by 52.8%, undermining growth credibility. Insider selling totaling $1.58M in the last six months, including multiple large sales by the CEO, reinforces bearish sentiment. The Graham Number of $5.21 and intrinsic value of $4.2 suggest deep undervaluation, but the current price of $15.15 reflects a premium driven by speculative growth expectations rather than fundamentals.
Key Strengths
Exceptional gross and operating margins (57.38% and 45.09%) indicate strong pricing power and cost control
High ROE of 35.56% demonstrates efficient use of equity capital
Low debt/equity ratio of 0.17 and high current ratio of 6.71 signal strong financial stability
Recent quarterly earnings have shown positive surprises, including a 62.5% beat in Q2 2024
Analyst consensus remains strong_buy, with a target price of $25.67, implying upside potential
Key Risks
Piotroski F-Score of 3/9 indicates weak financial health and high distress risk
Earnings have declined sharply by 52.8% YoY, contradicting revenue growth of 18.4%
Insider selling of $1.58M in six months, including multiple large sales by the CEO, signals lack of confidence
No Altman Z-Score available, but the low Piotroski score raises bankruptcy risk concerns
Stock trades at a premium to Graham Number ($5.21) and intrinsic value ($4.2), suggesting overvaluation
AI Fair Value Estimate
Based on comprehensive analysis
$4.2
-72.3% below current price
Performance Snowflake
Multi-dimensional AI analysis across 5 key categories
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Historical Performance Trends
Long-term financial metrics and growth patterns
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability, Growth & Financial Health
Detailed profit margins, ROE, debt ratios, and liquidity metrics
Sector Comparison & Peer Analysis
Compare ADMA against industry averages and similar companies
Insider Trading & Analyst Ratings
Track insider transactions and Wall Street analyst recommendations
Past News Coverage
Recent headlines mentioning ADMA from our newsroom.
Newest → oldest
No matching news yet.